

Table 14.6
De Novo Posttransplant Solid Malignancy, 1999 to 2008
Kidney Recipients

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Total # of Post-Tx Malignancies	1,046	1,100	1,016	897	825	754	621	477	263	93
Malignancies by Type										
Squamous/Basal Cell Carcinoma	569	562	510	470	414	389	287	240	135	48
Melanoma	30	37	26	29	30	21	16	17	12	6
Kaposi Sarcoma	7	10	8	2	5	6	3	5	2	1
Central Nervous System	8	9	12	9	4	5	6	4	2	1
Genito-Urinary (1)	154	163	142	137	122	113	105	67	39	14
Gastro-Intestinal (2)	95	77	71	55	54	53	49	43	19	8
Primary Hepatic Tumor	4	11	9	8	4	10	6	8	9	4
Metastatic Hepatic Tumor	9	13	19	14	12	8	10	8	4	1
Larynx/Bronchi/Lung	75	82	93	73	75	68	68	39	13	2
Breast/Thyroid	43	58	55	48	57	38	35	21	16	5
Leukemia	4	5	9	9	4	9	5	3	1	1
Sarcoma (3)	2	3	5	-	4	3	1	1	2	-
Other	36	55	47	34	25	29	25	16	9	2
Unknown	10	15	10	9	15	2	5	5	-	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	54.4%	51.1%	50.2%	52.4%	50.2%	51.6%	46.2%	50.3%	51.3%	51.6%
Melanoma	2.9%	3.4%	2.6%	3.2%	3.6%	2.8%	2.6%	3.6%	4.6%	6.5%
Kaposi Sarcoma	0.7%	0.9%	0.8%	0.2%	0.6%	0.8%	0.5%	1.0%	0.8%	1.1%
Central Nervous System	0.8%	0.8%	1.2%	1.0%	0.5%	0.7%	1.0%	0.8%	0.8%	1.1%
Genito-Urinary (1)	14.7%	14.8%	14.0%	15.3%	14.8%	15.0%	16.9%	14.0%	14.8%	15.1%
Gastro-Intestinal (2)	9.1%	7.0%	7.0%	6.1%	6.5%	7.0%	7.9%	9.0%	7.2%	8.6%
Primary Hepatic Tumor	0.4%	1.0%	0.9%	0.9%	0.5%	1.3%	1.0%	1.7%	3.4%	4.3%
Metastatic Hepatic Tumor	0.9%	1.2%	1.9%	1.6%	1.5%	1.1%	1.6%	1.7%	1.5%	1.1%
Larynx/Bronchi/Lung	7.2%	7.5%	9.2%	8.1%	9.1%	9.0%	11.0%	8.2%	4.9%	2.2%
Breast/Thyroid	4.1%	5.3%	5.4%	5.4%	6.9%	5.0%	5.6%	4.4%	6.1%	5.4%
Leukemia	0.4%	0.5%	0.9%	1.0%	0.5%	1.2%	0.8%	0.6%	0.4%	1.1%
Sarcoma (3)	0.2%	0.3%	0.5%	-	0.5%	0.4%	0.2%	0.2%	0.8%	-
Other	3.4%	5.0%	4.6%	3.8%	3.0%	3.8%	4.0%	3.4%	3.4%	2.2%
Unknown	1.0%	1.4%	1.0%	1.0%	1.8%	0.3%	0.8%	1.0%	-	-
Total # of Patients	718	738	717	661	612	575	490	382	216	78

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.